- Home
- CEE vs VERU Comparison
CEE vs VERU Comparison
Compare CEE & VERU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CEE
- VERU
- Stock Information
- Founded
- CEE 1990
- VERU 1971
- Country
- CEE Germany
- VERU United States
- Employees
- CEE N/A
- VERU N/A
- Industry
- CEE Finance Companies
- VERU Biotechnology: Pharmaceutical Preparations
- Sector
- CEE Finance
- VERU Health Care
- Exchange
- CEE Nasdaq
- VERU Nasdaq
- Market Cap
- CEE 97.8M
- VERU 94.5M
- IPO Year
- CEE N/A
- VERU 1990
- Fundamental
- Price
- CEE $15.55
- VERU $0.62
- Analyst Decision
- CEE
- VERU Strong Buy
- Analyst Count
- CEE 0
- VERU 2
- Target Price
- CEE N/A
- VERU $4.00
- AVG Volume (30 Days)
- CEE 22.0K
- VERU 3.1M
- Earning Date
- CEE 01-01-0001
- VERU 08-07-2025
- Dividend Yield
- CEE 3.86%
- VERU N/A
- EPS Growth
- CEE N/A
- VERU N/A
- EPS
- CEE N/A
- VERU N/A
- Revenue
- CEE N/A
- VERU $16,886,419.00
- Revenue This Year
- CEE N/A
- VERU N/A
- Revenue Next Year
- CEE N/A
- VERU N/A
- P/E Ratio
- CEE N/A
- VERU N/A
- Revenue Growth
- CEE N/A
- VERU 134.43
- 52 Week Low
- CEE $7.80
- VERU $0.45
- 52 Week High
- CEE $10.32
- VERU $1.42
- Technical
- Relative Strength Index (RSI)
- CEE 53.53
- VERU 58.35
- Support Level
- CEE $14.50
- VERU $0.56
- Resistance Level
- CEE $15.42
- VERU $0.65
- Average True Range (ATR)
- CEE 0.38
- VERU 0.05
- MACD
- CEE -0.02
- VERU 0.00
- Stochastic Oscillator
- CEE 83.84
- VERU 52.94
About CEE The Central and Eastern Europe Fund Inc. (The)
CENTRAL & EASTERN EUROPE FUND, INC. is a closed-end management investment company. The Fund's objective is to seek long-term capital appreciation. It invests in the equity or equity-linked securities of issuers domiciled in Central and Eastern Europe.
About VERU Veru Inc.
Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). The company is also in the late-stage development of certain drugs for the management of breast and prostate cancers. It also has a sexual health program that includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in a single segment and generates revenue from the USA which is the key revenue generating market, Brazil, and other regions.